Business Context and Reporting Period
This Form 8-K Current Report was filed by Lexeo Therapeutics, Inc. on January 27, 2026. The filing discloses significant changes to the company's executive leadership team, specifically the appointment of a new Chief Operating Officer and Chief Medical Officer, and the departure of a former executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Appointment of Chief Operating Officer: The Board appointed Jose Manuel Otero, Ph.D., previously the Chief Technical Officer, as Chief Operating Officer, effective January 2, 2026.
- Compensation Adjustment: In connection with his new role, Dr. Otero's annual base salary was approved at $510,000. He continues under his existing compensation arrangement otherwise.
- Appointment of Chief Medical Officer: The Board appointed Narinder P. Bhalla, M.D. as Chief Medical Officer, effective January 20, 2026.
- Executive Departure: Eric Adler, M.D., formerly Head of Research, ceased to be an executive officer effective January 27, 2026. He will transition to serve as President and CEO of Myoventive, Inc., a cardiac precision medicines company co-founded by Lexeo in June 2025. Dr. Adler will remain a senior clinical and scientific advisor to Lexeo.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, market outlook, or specific risk factors. It notes that there are no arrangements or understandings between Dr. Otero and other persons regarding his appointment, and he has no material interest in transactions requiring disclosure under Item 404(a) of Regulation S-K. The filing references a standard indemnification agreement for officers and directors.
Investor Verification Checklist
- Verify the biographical details of Dr. Otero and Dr. Bhalla in the Definitive Proxy Statement filed on April 28, 2025.
- Confirm the operational status and strategic focus of the newly formed spin-out, Myoventive, Inc.
- Review the impact of the leadership transition on ongoing clinical trials and research pipelines.
- Check subsequent filings for any additional compensation details or severance agreements related to Dr. Adler's departure.